All this sounds wonderful, but reminds me of people who have amazing systems to play the stock market and leverage $1,000 to $1,000,000. Of all the people with all their systems, a few lucky ones hit the jackpot by chance, while the majority muddle through or lose it all. The lucky ones assume the market has acknowledged their financial genius and go on to tell us all about it.
If 5% of glioblastoma patients uncannily survive, how much am I supposed to update on hearing that one of those patients did some combination of plausible but undertested interventions during their recovery?
Only 1 way to figure out: test it on (consenting) new patients. The drugs are generic (so cheap), and don’t have intolerable side effects. It has anecdotally worked. So it’s positive EV for patients with terminal prognosis. And yet its explained away as a curious ‘spontaneous’ remission, using your very valid objection.
This is after all my bigger claim / criticism of the status quo. My objective is to make a meta-level criticism more so than to advocate for one particular protocol as the potential cure. My claim is that a medical system that acted with urgency and that wanted to maximize patient survival odds, would have at the very least attempted to replicate the protocol in a Phase II clinical trial. Instead, it was ignored due to status quo bias. Not because it lacked a scientific justification, but because the drugs are generic.
In other words, I use the lack of a replication attempt to update in favor of systemic issues in oncology and FDA.
All this sounds wonderful, but reminds me of people who have amazing systems to play the stock market and leverage $1,000 to $1,000,000. Of all the people with all their systems, a few lucky ones hit the jackpot by chance, while the majority muddle through or lose it all. The lucky ones assume the market has acknowledged their financial genius and go on to tell us all about it.
If 5% of glioblastoma patients uncannily survive, how much am I supposed to update on hearing that one of those patients did some combination of plausible but undertested interventions during their recovery?
Only 1 way to figure out: test it on (consenting) new patients. The drugs are generic (so cheap), and don’t have intolerable side effects. It has anecdotally worked. So it’s positive EV for patients with terminal prognosis. And yet its explained away as a curious ‘spontaneous’ remission, using your very valid objection.
This is after all my bigger claim / criticism of the status quo. My objective is to make a meta-level criticism more so than to advocate for one particular protocol as the potential cure. My claim is that a medical system that acted with urgency and that wanted to maximize patient survival odds, would have at the very least attempted to replicate the protocol in a Phase II clinical trial. Instead, it was ignored due to status quo bias. Not because it lacked a scientific justification, but because the drugs are generic.
In other words, I use the lack of a replication attempt to update in favor of systemic issues in oncology and FDA.